The EPS decline likely left investors hesitant, as Sino Biopharmaceutical's performance, with a 34% loss including dividends, underperformed the broader market's 16% loss. This may signal unresolved challenges, given it's worse than the 6% annualised loss over the last half decade.
Sino Biopharmaceutical Limited's high P/S ratio may not be justified due to its slower revenue growth. Investors may hope for a business turnaround, but analysts lack confidence. The weak revenue outlook could risk the share price and shareholder investments.
Company's declining EPS, below market expectations, may have deterred investors. Past performance led to total loss for shareholders, raising future concerns. Dividend payouts, assumed reinvested, helped offset some losses.
SINO BIOPHARMACEUTに関するコメント
HSI Opens 109 pts Lower as WUXI Series Slip
$無錫薬明康徳(02359.HK)$ , whose net profit rose 21% in 2023, delayed two placing-funded investment projects by 2 years to the end of 2025, and its share price lost 2.8% to $41.55, while its sa...
まだコメントはありません